Wall Street broker Benchmark has raised its price target on a sneezing-listed compose cure (CMPO) to $ 24 from $ 17, citing Operational Momentum, growing M&A optionality and a key product upgrade from its Arculus Crypto Wallet Unit.
The stock was 2.7% higher in the early trade, about $ 21.
While investors have been waiting for a transformation purchase, CMPO shares have already risen about 61% years to date and surpassed the S&P 500, powered by improved execution, since Resolute Holdings took a majority share in September 2024, analyst Mark Palmer wrote.
Palmer pointed to Arculus’ new partnership with N. Exchange, a non-parenting authority, crypto trading platform, as evidence of the company’s strategic embrace of digital assets.
By integrating with multiple liquidity sites and launching a smart order -router, Arculus has improved its cold storage wallets to support effective trading along with secure detention.
The broker sees this positioning as a way of distinguishing arculus in a crowded market that especially appeals to corporate users who want custody, liquidity and execution in a single product.
The integration of advanced trading tools signalizes a shift from basic cold storage to a more dynamic offering. According to Benchmark, this Arculus puts in a stronger competitive position against both traditional wallet providers and exchanges with internal custody-lite solutions.
The broker repeated his purchase rating on the stock and projected FY26 adjusted EBITDA of $ 174.8 million on a $ 502.9 million revenue. It considers CMPO’s valuation as compelling, especially if crypto uptake accelerates and increases the demand for Arculus’ upgraded platform.
Read more: Billionaire Winklevoss Twins-supported Gemini launches self-defense smart wallet
